BR9908030A - Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado - Google Patents
Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicadoInfo
- Publication number
- BR9908030A BR9908030A BR9908030-3A BR9908030A BR9908030A BR 9908030 A BR9908030 A BR 9908030A BR 9908030 A BR9908030 A BR 9908030A BR 9908030 A BR9908030 A BR 9908030A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- cyclooxygenase
- disorder
- processes
- individual
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11033398P | 1998-11-30 | 1998-11-30 | |
PCT/US1999/028411 WO2000032189A1 (en) | 1998-11-30 | 1999-11-30 | Celecoxib compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9908030A true BR9908030A (pt) | 2000-11-28 |
Family
ID=22332446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9908030-3A BR9908030A (pt) | 1998-11-30 | 1999-11-30 | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado |
Country Status (47)
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9720061D0 (en) | 1997-09-19 | 1997-11-19 | Crosfield Joseph & Sons | Metal compounds as phosphate binders |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6403630B1 (en) * | 1999-01-27 | 2002-06-11 | Cornell Research Foundation, Inc. | Treating cancers associated with overexpression of HER-2/neu |
SK12682001A3 (sk) | 1999-12-08 | 2002-07-02 | Pharmacia Corporation, Corporate Patent Department | Celecoxib v tuhej forme so zvýšenou biologickou dostupnosťou |
US7172769B2 (en) * | 1999-12-08 | 2007-02-06 | Pharmacia Corporation | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
CN1679556A (zh) * | 1999-12-08 | 2005-10-12 | 法马西亚公司 | 维得克西组合物 |
CA2394232C (en) * | 1999-12-22 | 2009-06-09 | Subhash Desai | Dual-release compositions of a cyclooxygenase-2-inhibitor |
EP1239856A1 (en) * | 1999-12-22 | 2002-09-18 | Pharmacia Corporation | Sustained-release formulation of a cyclooxygenase-2 inhibitor |
MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
AU2001275004A1 (en) * | 2000-06-01 | 2001-12-11 | Pharmacia Corporation | Use of cox2 inhibitors for treating skin injury from exposure to ultraviolet radiation |
CA2409123A1 (en) * | 2000-06-08 | 2001-12-13 | The University Of Texas System | Heterocycle derivatives and methods of use |
US6589557B2 (en) * | 2000-06-15 | 2003-07-08 | Acusphere, Inc. | Porous celecoxib matrices and methods of manufacture thereof |
CN1638739A (zh) * | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
NZ524124A (en) * | 2000-08-18 | 2004-09-24 | Pharmacia Corp | Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
IN191090B (pt) * | 2000-08-29 | 2003-09-20 | Ranbanx Lab Ltd | |
PE20020351A1 (es) * | 2000-09-11 | 2002-06-14 | Novartis Ag | Composiciones farmaceuticas que comprenden acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico como inhibidor de la ciclooxigenasa-2 |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
PL205343B1 (pl) | 2001-01-26 | 2010-04-30 | Schering Corp | Zastosowanie inhibitora wchłaniania sterolu |
SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
UA80682C2 (en) * | 2001-08-06 | 2007-10-25 | Pharmacia Corp | Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition |
US20030114527A1 (en) * | 2001-08-31 | 2003-06-19 | Karnachi Anees Abdulquadar | Pharmaceutical composition |
US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
AU2002361596A1 (en) * | 2001-11-07 | 2003-05-19 | Pharmacia Corporation | Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
EP1490030B2 (en) * | 2002-03-20 | 2010-07-14 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
GB0209257D0 (en) * | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
US6864373B2 (en) | 2002-05-13 | 2005-03-08 | Pharmacia Corporation | Stable amorphous celecoxib composite and process therefor |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
WO2004014431A1 (en) * | 2002-08-12 | 2004-02-19 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
JP2006514687A (ja) * | 2002-08-30 | 2006-05-11 | ファルマシア コーポレイション | 再現性のある医薬放出特性を示す医薬固形投与形態 |
MXPA05004811A (es) | 2002-11-06 | 2005-07-22 | Schering Corp | Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes. |
EP1839654B9 (de) | 2002-11-22 | 2012-01-11 | Grünenthal GmbH | Verwendung von (1R, 2R)-3-(3-Dimenthylamino-1-ethyl-2-methyl-propyl)-phenol zur Behandlung von Entzündungsschmerz |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US20060172019A1 (en) * | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
WO2004081004A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
DE602004018617D1 (de) | 2003-03-07 | 2009-02-05 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
US20040220187A1 (en) * | 2003-04-22 | 2004-11-04 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders |
US6916852B2 (en) * | 2003-05-12 | 2005-07-12 | University Of Tennessee Research Foundation | Method for regulation of microvascular tone |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
WO2005095349A1 (en) * | 2004-04-01 | 2005-10-13 | Pharmacia & Upjohn Company Llc | Crystalline pyrazole derivative |
TR200701266T1 (tr) * | 2004-09-09 | 2007-06-21 | Bayer Animal Health Gmbh | Farmasötik bileşim. |
WO2006056770A1 (en) | 2004-11-23 | 2006-06-01 | Pliva Hrvatska D.O.O. | Extended release pharmaceutical composition of celecoxib |
MY157620A (en) | 2006-01-31 | 2016-06-30 | Cytochroma Dev Inc | A granular material of a solid water-soluble mixed metal compound capable of binding phosphate |
RU2309732C1 (ru) | 2006-03-13 | 2007-11-10 | Олег Ильич Эпштейн | Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата |
TWI394753B (zh) | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | 新穎替妥牟拉(tetomilast)晶體 |
EP2132173B1 (en) * | 2007-02-26 | 2015-10-07 | Merck Sharp & Dohme Corp. | Formulations for cathepsin k inhibitors |
AR065802A1 (es) * | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
GB0714670D0 (en) | 2007-07-27 | 2007-09-05 | Ineos Healthcare Ltd | Use |
GB0720220D0 (en) | 2007-10-16 | 2007-11-28 | Ineos Healthcare Ltd | Compound |
US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
US20100233272A1 (en) * | 2007-11-15 | 2010-09-16 | Leah Elizabeth Appel | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
US8377453B2 (en) | 2008-03-11 | 2013-02-19 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
US8372432B2 (en) | 2008-03-11 | 2013-02-12 | Depomed, Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
EP2399238B1 (en) * | 2009-02-17 | 2015-06-17 | Koninklijke Philips N.V. | Functional imaging |
PL387415A1 (pl) * | 2009-03-06 | 2010-09-13 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania |
MA33297B1 (fr) * | 2009-04-24 | 2012-05-02 | Iceutica Pty Ltd | Production de nanoparticules encapsulées à des fractions volumiques élevées |
WO2010121322A1 (en) * | 2009-04-24 | 2010-10-28 | Iceutica Pty Ltd | Production of encapsulated nanoparticles at commercial scale |
BRPI1013835B8 (pt) * | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | método para produção de material biologicamente ativo de nanopartícula e/ou micropartícula, composição compreendendo referido material, composição farmacêutica, uso da mesma, e, método para produção de uma composição farmacêutica, de um produto veterinário e de um produto agrícola |
CA2759104C (en) * | 2009-04-24 | 2019-01-29 | Iceutica Pty Ltd | Method for improving the dissolution profile of a biologically active material |
CN104188909A (zh) * | 2009-04-24 | 2014-12-10 | 伊休蒂卡有限公司 | 用于制备商品化纳米颗粒和微粒粉末的方法 |
EP2432459A2 (en) * | 2009-05-20 | 2012-03-28 | Ranbaxy Laboratories Limited | Oral compositions of celecoxib |
GB0913525D0 (en) | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
WO2011050944A1 (en) | 2009-10-28 | 2011-05-05 | Ratiopharm Gmbh | Formulations containing celecoxib |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
US9198861B2 (en) | 2009-12-22 | 2015-12-01 | Mallinckrodt Llc | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
EP2340818A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of venlafaxine and celecoxib |
GB201001779D0 (en) | 2010-02-04 | 2010-03-24 | Ineos Healthcare Ltd | Composition |
CN102000018B (zh) * | 2010-02-09 | 2012-07-04 | 浙江大学宁波理工学院 | 一种含塞来昔布的固体分散物及其制备方法和应用 |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
US8658631B1 (en) | 2011-05-17 | 2014-02-25 | Mallinckrodt Llc | Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia |
US20140093563A1 (en) * | 2011-06-13 | 2014-04-03 | Ranbaxy Laboratories Limited | Febuxostat compositions |
CN102949402A (zh) * | 2011-08-24 | 2013-03-06 | 天津药物研究院 | 一种塞来昔布组合物及制备方法和用途 |
CN102949403A (zh) * | 2011-08-24 | 2013-03-06 | 天津药物研究院 | 一种塞来昔布组合物及制备方法和用途 |
CN102920676B (zh) * | 2012-12-04 | 2014-08-20 | 山东省立医院 | 一种塞来昔布咀嚼片及其制备方法 |
CN103989657B (zh) * | 2013-02-20 | 2016-10-05 | 四川国为制药有限公司 | 一种含有塞来昔布的胶囊剂 |
AU2013381866A1 (en) * | 2013-03-15 | 2015-09-24 | The Penn State Research Foundation | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer |
CN103230382B (zh) * | 2013-04-17 | 2015-12-09 | 贵州联盛药业有限公司 | 塞来昔布泡腾片及其制备方法 |
CN103585164B (zh) * | 2013-11-08 | 2015-12-02 | 海南合瑞制药股份有限公司 | 一种溶出度增加的塞来昔布固体组合物及其制备方法和应用 |
CN104027319A (zh) * | 2014-06-25 | 2014-09-10 | 万特制药(海南)有限公司 | 一种塞来昔布分散片及其制备方法 |
KR101652332B1 (ko) | 2014-10-31 | 2016-09-01 | (주) 킴스제약 | 관절염 치료용 혼합조성물 및 관절염 치료용 혼합제제의 제조방법 |
CN104721146A (zh) * | 2015-04-03 | 2015-06-24 | 海南海力制药有限公司 | 塞来昔布溶剂分散体、微丸胶囊及其制备方法 |
KR101994129B1 (ko) | 2015-05-28 | 2019-06-28 | 닥터 레디스 레보러터리즈 리미티드 | 통증 치료를 위한 셀레콕시브 경구용 조성물 |
KR101710792B1 (ko) | 2015-07-14 | 2017-02-28 | 주식회사 유영제약 | 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물 |
CN104983714A (zh) * | 2015-08-06 | 2015-10-21 | 苏州二叶制药有限公司 | 一种塞来昔布胶囊及其制备方法 |
CN105125520A (zh) * | 2015-09-29 | 2015-12-09 | 深圳瑞多力泰医药科技实业有限公司 | 一种塞来昔布制剂及其制备方法和控制方法 |
HUP1500618A2 (en) | 2015-12-16 | 2017-06-28 | Druggability Tech Ip Holdco Ltd | Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them |
CN105343030A (zh) * | 2015-12-16 | 2016-02-24 | 钟柏根 | 一种塞来昔布胶囊及其制备方法 |
KR101625344B1 (ko) | 2015-12-21 | 2016-06-08 | 주식회사 유영제약 | 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물 |
US20170348419A1 (en) * | 2016-06-06 | 2017-12-07 | NuBioPharma, LLC | Oral liquid suspensions |
KR102002906B1 (ko) * | 2016-10-18 | 2019-07-23 | 경동제약 주식회사 | 셀레콕시브를 포함하는 정제 |
US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
MX2021007780A (es) * | 2018-12-28 | 2021-12-15 | Gnt Pharma Co Ltd | Composiciones y metodos para tratar trastornos neurodegenerativos. |
WO2020214791A1 (en) * | 2019-04-18 | 2020-10-22 | Nangenex Nanotechnology Incorporated | Celecoxib compositions and methods for their use |
CN110604722B (zh) * | 2019-09-19 | 2020-12-11 | 山东创新药物研发有限公司 | 一种塞来昔布的固体分散方法及塞来昔布胶囊的制备方法 |
TW202140014A (zh) * | 2020-01-16 | 2021-11-01 | 日商衛材R&D企管股份有限公司 | 萊博雷生的原料藥及含有其的醫藥組成物 |
CN112263562B (zh) * | 2020-09-25 | 2022-09-30 | 石药集团欧意药业有限公司 | 一种塞来昔布胶囊组合物的制备方法 |
WO2022131844A1 (ko) * | 2020-12-18 | 2022-06-23 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민을 포함하는 신규한 경구투여용 제제 |
CN112933085B (zh) * | 2020-12-28 | 2021-12-21 | 中以海德人工智能药物研发股份有限公司 | 一种化合物在制备治疗或预防病毒性肝炎用药物中的应用 |
CA3144079A1 (en) | 2020-12-28 | 2022-06-28 | Biodelivery Sciences International, Inc. | Methods of treating pain |
CN113402463B (zh) * | 2021-07-08 | 2023-12-26 | 江南大学 | 一种塞来昔布微晶、负载塞来昔布微晶的温敏性凝胶及其制备方法 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5644A (en) * | 1848-06-20 | Improvement in apparatus for the increase of the speed of vessels | ||
EP0001247A1 (en) | 1977-09-14 | 1979-04-04 | Kanebo, Ltd. | Pharmaceutical preparation containing nifedipine and a method for producing the same. |
US5264446A (en) * | 1980-09-09 | 1993-11-23 | Bayer Aktiengesellschaft | Solid medicament formulations containing nifedipine, and processes for their preparation |
DE3270785D1 (en) * | 1981-10-29 | 1986-05-28 | Bayer Ag | Process for preparing solid fast-releasing drug formulations of dihydropyridines |
IT1206166B (it) * | 1984-07-26 | 1989-04-14 | Sigma Tau Ind Farmaceuti | Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US5266581A (en) | 1984-07-04 | 1993-11-30 | Bayer Aktiengesellschaft | Solid composition containing dihydropyridine, PVP and PVPP |
IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US4666705A (en) * | 1985-06-03 | 1987-05-19 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5112619A (en) | 1985-11-12 | 1992-05-12 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulation |
US4971790A (en) | 1986-02-07 | 1990-11-20 | Alza Corporation | Dosage form for lessening irritation of mocusa |
DE3610037A1 (de) * | 1986-03-21 | 1987-09-24 | Schering Ag | Nifedipinkombinationspraeparat |
FR2602423B1 (fr) | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
IT1201136B (it) * | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
GB8702411D0 (en) | 1987-02-03 | 1987-03-11 | Zyma Sa | Swellable pellets |
US4786503A (en) * | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
IT1215726B (it) | 1988-01-18 | 1990-02-22 | Alfa Wassermann Spa | Formulazioni galeniche a cessione programmata. |
FR2627696B1 (fr) * | 1988-02-26 | 1991-09-13 | Fournier Innovation Synergie | Nouvelle forme galenique du fenofibrate |
US4866848A (en) * | 1988-10-24 | 1989-09-19 | Alexander Agelidis | Instrument for subdividing angles into halves, thirds or fifths |
US5342624A (en) * | 1989-02-16 | 1994-08-30 | British Technology Group Ltd. | Dispensing device |
HU203041B (en) * | 1989-03-14 | 1991-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
US5776493A (en) * | 1989-07-14 | 1998-07-07 | Alza Corporation | Oral osmotic device for delivery of nystatin with hydrogel driving member |
US5474784A (en) * | 1990-03-02 | 1995-12-12 | British Technology Group Limited | Dispensing device |
FR2669915B1 (fr) | 1990-11-29 | 1993-01-29 | Atochem | Particules de chlorure de magnesium a structure polyedre, composante catalytique supportee sur ces particules, procedes de fabrication de ces produits et des polyolefines obtenues a partir de cette composante catalytique. |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US6048850A (en) | 1992-09-22 | 2000-04-11 | Young; Donald A. | Method of inhibiting prostaglandin synthesis in a human host |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5540669A (en) * | 1993-09-30 | 1996-07-30 | Becton, Dickinson And Company | Iontophoretic drug delivery system and method for using same |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
DE69422306D1 (de) * | 1993-11-30 | 2000-01-27 | Searle & Co | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen |
JP2788677B2 (ja) | 1994-01-10 | 1998-08-20 | メルク フロスト カナダ インコーポレーテツド | Cox−2阻害剤としてのフェニル複素環 |
US5543099A (en) * | 1994-09-29 | 1996-08-06 | Hallmark Pharmaceutical, Inc. | Process to manufacture micronized nifedipine granules for sustained release medicaments |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5633272A (en) * | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
TW493991B (en) | 1995-05-08 | 2002-07-11 | Novartis Ag | Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same |
RU2251543C2 (ru) | 1995-05-25 | 2005-05-10 | Джи.Ди.Сирл энд Ко. | Дикетон в качестве промежуточного продукта при получении 3-галоген-1н-пиразолов |
US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US5756529A (en) * | 1995-09-29 | 1998-05-26 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
EE03746B1 (et) * | 1996-05-17 | 2002-06-17 | Merck & Co., Inc. | Farmatseutiline kompositsioon tsüklooksügenaas-2 vahendatud haiguste raviks, 3-fenüül-4-(4-(metüülsulfonüül) fenüül)-2-(5H)-furanooni kasutamine ja ühikuline oraalne doseerimisvorm |
US6586458B1 (en) * | 1996-08-16 | 2003-07-01 | Pozen Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
KR100212449B1 (ko) * | 1996-10-09 | 1999-08-02 | 이계철 | 무궁화 위성방송의 송/수신기 정합 방법 |
US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
EP0863134A1 (en) * | 1997-03-07 | 1998-09-09 | Merck Frosst Canada Inc. | 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2 |
US20030225150A1 (en) * | 1997-04-21 | 2003-12-04 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia |
CN1264376A (zh) * | 1997-05-22 | 2000-08-23 | G·D·瑟尔公司 | 作为p38激酶抑制剂的3(5)-杂芳基取代的吡唑化合物 |
WO1999009988A1 (en) * | 1997-08-27 | 1999-03-04 | Hexal Ag | New pharmaceutical compositions of meloxicam with improved solubility and bioavailability |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
CA2343148C (en) * | 1998-09-10 | 2005-11-15 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
US6440967B1 (en) * | 1998-11-12 | 2002-08-27 | Merck & Co., Inc. | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
WO2000048583A2 (en) | 1999-02-19 | 2000-08-24 | Pozen Inc. | Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine |
-
1999
- 1999-04-05 SA SA99191255A patent/SA99191255B1/ar unknown
- 1999-11-26 TN TNTNSN99223A patent/TNSN99223A1/fr unknown
- 1999-11-29 PE PE1999001189A patent/PE20001349A1/es active IP Right Grant
- 1999-11-29 MA MA25858A patent/MA26709A1/fr unknown
- 1999-11-29 AR ARP990106069A patent/AR020015A1/es not_active Application Discontinuation
- 1999-11-30 EP EP99961890A patent/EP1049467B1/en not_active Revoked
- 1999-11-30 GE GEAP19995492A patent/GEP20022784B/en unknown
- 1999-11-30 ES ES99961890T patent/ES2185412T3/es not_active Expired - Lifetime
- 1999-11-30 CA CA002319201A patent/CA2319201C/en not_active Expired - Lifetime
- 1999-11-30 HN HN1999000210A patent/HN1999000210A/es unknown
- 1999-11-30 UA UA2000074568A patent/UA58576C2/uk unknown
- 1999-11-30 GT GT199900203A patent/GT199900203A/es unknown
- 1999-11-30 UY UY25826A patent/UY25826A1/es not_active Application Discontinuation
- 1999-11-30 PA PA19998486001A patent/PA8486001A1/es unknown
- 1999-11-30 DE DE69903404T patent/DE69903404T2/de not_active Revoked
- 1999-11-30 AT AT99961890T patent/ATE225650T1/de not_active IP Right Cessation
- 1999-11-30 PL PL341372A patent/PL200957B1/pl unknown
- 1999-11-30 EA EA200000718A patent/EA003363B1/ru not_active IP Right Cessation
- 1999-11-30 ME MEP-2008-544A patent/ME00416B/me unknown
- 1999-11-30 JP JP2000584884A patent/JP3563036B2/ja not_active Expired - Lifetime
- 1999-11-30 RS YUP-486/00A patent/RS50158B/sr unknown
- 1999-11-30 EE EEP200000437A patent/EE04834B1/xx not_active IP Right Cessation
- 1999-11-30 TR TR2000/02207T patent/TR200002207T1/xx unknown
- 1999-11-30 OA OA1200000200A patent/OA11616A/en unknown
- 1999-11-30 BR BR9908030-3A patent/BR9908030A/pt not_active Application Discontinuation
- 1999-11-30 DK DK99961890T patent/DK1049467T3/da active
- 1999-11-30 GC GCP1999388 patent/GC0000114A/xx active
- 1999-11-30 IL IL13653299A patent/IL136532A/xx unknown
- 1999-11-30 NZ NZ505762A patent/NZ505762A/en not_active IP Right Cessation
- 1999-11-30 CN CNB2004100375225A patent/CN1299683C/zh not_active Ceased
- 1999-11-30 PT PT99961890T patent/PT1049467E/pt unknown
- 1999-11-30 AP APAP/P/2000/001874A patent/AP1637A/en active
- 1999-11-30 KR KR10-2000-7008340A patent/KR100501034B1/ko not_active Ceased
- 1999-11-30 SK SK1106-2000A patent/SK283510B6/sk not_active IP Right Cessation
- 1999-11-30 AU AU18381/00A patent/AU748851B2/en not_active Expired
- 1999-11-30 WO PCT/US1999/028411 patent/WO2000032189A1/en not_active Application Discontinuation
- 1999-11-30 HU HU0100867A patent/HUP0100867A3/hu not_active Application Discontinuation
- 1999-11-30 CN CNB998021857A patent/CN1154490C/zh not_active Ceased
- 1999-11-30 KR KR10-2004-7009987A patent/KR20040065307A/ko not_active Ceased
- 1999-11-30 HR HR20000434A patent/HRP20000434B1/xx not_active IP Right Cessation
- 1999-11-30 SI SI9930144T patent/SI1049467T1/xx unknown
-
2000
- 2000-01-25 TW TW088120791A patent/TW579295B/zh not_active IP Right Cessation
- 2000-02-23 UY UY26025A patent/UY26025A1/es not_active Application Discontinuation
- 2000-05-31 ZA ZA200002722A patent/ZA200002722B/en unknown
- 2000-06-30 IS IS5555A patent/IS5555A/is unknown
- 2000-07-24 CU CU20000176A patent/CU20000176A7/es unknown
- 2000-07-25 NO NO20003815A patent/NO329912B1/no not_active IP Right Cessation
- 2000-07-27 CR CR6210A patent/CR6210A/es unknown
- 2000-08-09 BG BG104680A patent/BG64938B1/bg unknown
-
2004
- 2004-02-11 US US10/776,869 patent/US20050267189A1/en not_active Abandoned
-
2008
- 2008-01-14 US US12/013,873 patent/US20080167362A1/en not_active Abandoned
- 2008-03-28 CR CR9842A patent/CR9842A/es not_active Application Discontinuation
-
2012
- 2012-03-13 US US13/418,852 patent/US20120171284A1/en not_active Abandoned
-
2014
- 2014-09-23 US US14/493,921 patent/US9750756B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9908030A (pt) | Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado | |
BR0012136A (pt) | Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos | |
BR0113447A (pt) | Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica | |
BR0008060A (pt) | Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica | |
BR0314308A (pt) | Composto, composição farmacêutica, métodos para bloquear uma combinação de mu, kappa, delta ou receptor (heterodìmero) dos mesmos em mamìferos, para tratar ou prevenir obesidade e doenças relacionadas, para suprimir o apetite em um paciente em necessidade deste, e para realizar a perda de peso em um paciente obeso, e, uso de um composto | |
BR9814389A (pt) | Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso | |
BR0008059A (pt) | Composições de valdecoxib | |
BRPI0317463B8 (pt) | composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina | |
BR9911073A (pt) | Uso de uma composição compreendendo formoterol e budesonida para a prevenção ou tratamento de uma condição aguda de asma | |
CA2442168A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
BR0008058A (pt) | Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada | |
BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
MY117892A (en) | Therapeutic compounds | |
BR0008847A (pt) | Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas | |
BR9709838A (pt) | Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase | |
KR970061244A (ko) | 치매 치료용 약학 조성물 | |
MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
BR9608435A (pt) | Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas. | |
SE7612534L (sv) | Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning | |
MX9501849A (es) | Nuevos compuestos biciclicos-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos. | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
MX9805441A (es) | Compuestos terapeuticos. | |
MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
BR9908885A (pt) | Medicamento para a profilaxia e/ou tratamento de mastocarcinoma, compreendendo um inibidor esteróide de aromatase | |
BR112023000598A2 (pt) | Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT. CL.: A61K 9/14; A61K 9/20; A61K 31/415; A61K 31/18. Ipc: A61K 9/14 (2008.04), A61K 9/20 (2008.04), A61K 31/ |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE AS REIVINDICACOES 1 E SUAS DEPENDENTES ( 2 - 7 ) E INTERLIGADAS ( 8 E 9 ), NAO APRESENTAM O REQUISITO DE ATIVIDADE INVENTIVA, COMO DISPOSTO NOS ARTIGOS 8O E 13 DA LEI 9.279/96. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA INT.CL: A61K 9/14, A61K 9/20, A61K 31/415, A61K 31/18, A61P 29/00 Ipc: A61K 9/14 (2011.01), A61K 9/20 (2011.01), A61K 31/ |
|
B15W | Others matters related to applications: legal action concerning application |
Free format text: INPI-52400.104145/2014-83 ORIGEM: JUIZO DA 031A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0147752-50.2013.4.02.5101 ACAO ORDINARIA DE NULIDADE DA DECISAO ADMINISTRATIVA QUE MANTEVE O INDEFERIMENTO DO PEDIDO AUTOR: G.D. SEARLE LLC REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA. |
|
B15N | Others concerning applications: notification of judicial decision |
Free format text: INPI-52400.104145/2014-83 SECAO JUDICIARIA DO ESTADO DO RIO DE JANEIRO 31A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0147752-50.2013.4.02.5101AUTOR: G.D. SEARLE LLC REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI E AGENCIA NACIONAL DE VIGILANCIA SANITARIA - ANVISA DECISAO: DIANTE DO EXPOSTO, NOS TERMOS DA FUNDAMENTACAO, JULGO:I) EXTINTO O PROCESSO, SEM RESOLUCAO DO MERITO, NOS TERMOS DO ART.485, VI DO CPC, NO TOCANTE AO PEDIDO AUTORAL PARA DETERMINAR A ANVISA QUE ANUA O PEDIDO, FORMA DO DISPOSTO ART.229-C DA LPI.II) JULGO PARCIALMENTE PROCEDENTE O PEDIDO, PARA DECLARAR NULO O ATO ADMINISTRATIVO DE INDEFERIMENTO DA PATENTE PI 9908030-3, NOS TERMOS DO ART.487, I, DO CPC. |
|
B150 | Others concerning applications: publication cancelled [chapter 15.30 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 15.14 NA RPI NO 2531 DE 09/07/2019 POR TER SIDO INDEVIDA, CONFORME O DISPOSTO A FOLHA 164 DO PROCESSO ADMINISTRATIVO INPI 52400.104145/2014-83, REFERENTE A ACAO JUDICIAL NO 0147752-50.2013.4.02.5101. |